No Photo Available

Last Update

2016-08-19T00:00:00.000Z

This profile was last updated on .

Is this you? Claim your profile.

Wrong Richard Sherman?

Mr. Richard L. Sherman

Senior Vice President, Strategic Transactions and General Counsel

TETRALOGIC PHARMACEUTICALS CORP

HQ Phone: (610) 889-9900

Email: r***@***.com

Get ZoomInfo Grow

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

TETRALOGIC PHARMACEUTICALS CORP

343 Phoenixville Pike

Malvern, Pennsylvania 19355

United States

Company Description

TetraLogic is a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule therapeutics in oncology and infectious diseases. TetraLogic has two clinical-stage product candidates in development: birinapant and SHAPE ... more

Find other employees at this company (25)

Background Information

Employment History

ThinkTechHawaii Inc

Deputy General Counsel

SmithKline Beckman Corporation

Vice President

Malvern Consulting Group , Inc.

Affiliations

Board Member
Sbarro Health Research Organization

Board Member
Leversense LLC

Board Member
The Saint Andrew Society of Hawaii

Advisor
Diagenetix Inc

Member, Boards of UH Connections, MarBec Marine Sciences Consortium
Advisory

Active Member
Board

Board Member
HiBEAM company

Board Member
Pennsylvania Biotechnology Association

Member of the Board of Trustees
Crossroads Schools

Board Member
Hawaii Venture Capital Association

Board Member
Hawaii Science & Technology Council

Member
Pennsylvania Bar Association

Board Member
Hawaii Biotech , Inc.

Board Member
Cyto-Med Inc

Board Member
IBAH , Inc.

Member of the Advisory Board
University of Hawaii Medical School

Technology Advisory Board
The Children's Hospital of Philadelphia

Board Member
Sparta Pharmaceuticals

Board Member
Kenna Technologies , Inc.

Board Member
Mera Pharmaceuticals Inc

Board Member
Immunomedics , Inc.

Board Member
Functional Technologies Corp

Executive Board
START Technology Partnership

Member of the Investment Advisory Committee
Ben Franklin Technology Partners

Advisory Board
University of Hawai'i John A. Burns School of Medicine

Board Member
Aloha Medical Mission

Board Member
Aquasearch , Inc.

Education

B.A.

political science and economics

University of Nebraska

JD

Juris Doctor

New York University School of Law

law degree

New York University School of Law

Web References (184 Total References)


Immunomedics - Company Bios

www.immunomedics.com [cached]

Richard L. Sherman is Senior Vice President, Strategic Transactions and General Counsel of TetraLogic Pharmaceuticals Corporation, a privately held biopharmaceutical company that focuses on the discovery and development of SMAC mimetics, small molecule peptide-mimetic drugs that mimic SMAC (second mitochondrial-derived activator of caspases), for the treatment of cancers and certain other diseases. Mr. Sherman also serves as a consultant to the law firm of Goodsill Anderson Quinn & Stifel. Prior to joining TetraLogic in 2012, Mr. Sherman provided consulting services to TetraLogic as Vice President, Strategic Partnering and Transactions at Malvern Consulting Group. From 1976 through 1989, Mr. Sherman served as Deputy General Counsel of SmithKline Beckman Corporation (now GlaxoSmithKline). From 1990 through 1992, he was a partner in the law firm of Pepper Hamilton LLP. In addition, from 1992 through 2001, Mr. Sherman was founder and managing officer of QED Technologies, Inc., a life science business consulting firm purchased in 1999 by The Omnicom Group. Mr. Sherman is also a principal in a private SBIC Investment fund, CIP Capital, L.P., and a venture partner in the SCP/Vitalife family of funds in suburban Philadelphia. Mr. Sherman is currently a member of the Board of Directors of Hawaii Biotech, Inc, a privately held company that develops prophylactic vaccines for infectious diseases.


Richard L. Sherman, ...

www.sec.gov [cached]

Richard L. Sherman, J.D

...
Richard L. Sherman, J.D. joined us as General Counsel in November 2012 and previously provided consulting services to us as Vice President, Strategic Partnering and Transactions at Malvern Consulting Group from February 2012 through October 2012. He was appointed as Secretary in September 2013. Prior to joining us, Mr. Sherman served as General Counsel at Actinium Pharmaceuticals, Inc. from June 2004 through September 2012 and General Counsel at Hawaii Biotech, Inc., or Hawaii Biotech, from January 2002 through July 2010. From 1992 through 2001, he was the founder and managing officer of QED Technologies, L.P., a life science business consulting firm purchased in 1999 by The Omnicom Group. Mr. Sherman was a partner in the law firm of Pepper, Hamilton & Scheetz (now Pepper Hamilton LLP) from 1990 through 1992. He also spent more than a decade as Deputy General Counsel of SmithKline Beckman Corporation (now GlaxoSmithKline), from 1976 through 1989.
Mr. Sherman is also a principal in a private Small Business Investment Company investment fund, CIP Capital L.P., and a venture partner in the SCP/Vitalife family of funds in suburban Philadelphia. Mr. Sherman currently serves as a member of the board of directors of Hawaii Biotech (2005 to present) and Immunomedics, Inc. (NASDAQ: IMMU) (August 2013 to present) and formerly served as a member of the board of directors of Functional Technologies, Inc. (May 2011 to June 2013) and Leversense LLC (March 2011 to February 2013). He graduated magna cum laude with a B.A. in political science and economics from the University of Nebraska in 1968, where he was elected to Phi Beta Kappa. As a Root-Tilden Scholar at the New York University School of Law, he received his Juris Doctor degree in 1971.


Immunomedics - Company Bios

www.immunomedics.com [cached]

Richard L. Sherman is Senior Vice President, Strategic Transactions and General Counsel of TetraLogic Pharmaceuticals Corporation, a privately held biopharmaceutical company that focuses on the discovery and development of SMAC mimetics, small molecule peptide-mimetic drugs that mimic SMAC (second mitochondrial-derived activator of caspases), for the treatment of cancers and certain other diseases. Mr. Sherman also serves as a consultant to the law firm of Goodsill Anderson Quinn & Stifel. Prior to joining TetraLogic in 2012, Mr. Sherman provided consulting services to TetraLogic as Vice President, Strategic Partnering and Transactions at Malvern Consulting Group. From 1976 through 1989, Mr. Sherman served as Deputy General Counsel of SmithKline Beckman Corporation (now GlaxoSmithKline). From 1990 through 1992, he was a partner in the law firm of Pepper Hamilton LLP. In addition, from 1992 through 2001, Mr. Sherman was founder and managing officer of QED Technologies, Inc., a life science business consulting firm purchased in 1999 by The Omnicom Group. Mr. Sherman is also a principal in a private SBIC Investment fund, CIP Capital, L.P., and a venture partner in the SCP/Vitalife family of funds in suburban Philadelphia. Mr. Sherman is currently a member of the Board of Directors of Hawaii Biotech, Inc, a privately held company that develops prophylactic vaccines for infectious diseases.


> Richard L. Sherman, ...

tetralogicpharma.com [cached]

> Richard L. Sherman, JD

...
Richard L. Sherman, JD General Counsel
Mr. Sherman joined TetraLogic Pharmaceuticals in 2012 and previously provided consulting services to TetraLogic as Vice President, Strategic Partnering and Transactions at Malvern Consulting Group. He spent more than a decade (1976-1989) as Deputy General Counsel of SmithKline Beckman Corporation (now GlaxoSmithKline), was a partner in the law firm of Pepper Hamilton LLP (1990-1992), and was founder and managing officer (1992-2001) of QED Technologies, Inc., a life science business consulting firm purchased in 1999 by The Omnicom Group in New York. He is a principal in a private SBIC Investment fund, CIP Capital, L.P. and a venture partner in the SCP/Vitalife family of funds in suburban Philadelphia. Mr. Sherman has served on the Board of Directors of a number of for-profit companies, including Biophage, Inc., CytoMed, Inc., IBAH, Inc., Kenna Technologies, Inc., Mera Pharmaceuticals, Inc., and Sparta Pharmaceuticals. He is currently a member of the Board of Directors of Functional Technologies Corp., a Vancouver based publicly traded company, Hawaii Biotech, Inc. and Leversense LLC. Mr. Sherman graduated magna cum laude from the University of Nebraska (1968), where he was elected to Phi Beta Kappa. As a Root-Tilden Scholar at the New York University School of Law, he received his Juris Doctor in 1971.


/s/ RICHARD L. ...

ir.tetralogicpharma.com [cached]

/s/ RICHARD L. SHERMAN

...
Richard L. Sherman Secretary
...
IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS FOR THE STOCKHOLDER MEETING TO BE HELD ON FRIDAY, MAY 16, 2014: Copies of this Proxy Statement and the accompanying form of proxy card, and the enclosed 2013 Annual Report on Form 10-K (the "Annual Report") are available without charge at www.proxyvote.com, by telephone at 1-800-579-1639, or by notifying our Secretary, Richard L. Sherman, in writing, at TetraLogic Pharmaceuticals Corporation, 343 Phoenixville Pike, Malvern, PA 19355.
...
If you would like to inspect the list, please call Richard L. Sherman, our Secretary, at 610-889-9900 to arrange a visit to our offices.
...
By using any of the methods discussed above, you will be appointing as your proxies J. Kevin Buchi, our President and Chief Executive Officer, and Richard L. Sherman, our Senior Vice President, Strategic Transactions, General Counsel and Secretary.
...
A registered stockholder may change his or her vote or revoke his or her proxy at any time before the Annual Meeting by (i) notifying our Secretary, Richard L. Sherman, in writing, at TetraLogic Pharmaceuticals Corporation, 343 Phoenixville Pike, Malvern, PA 19355, that you revoke your
...
Richard L. Sherman, J.D
...
Richard L. Sherman, J.D. joined us as General Counsel in November 2012 and previously provided consulting services to us as Vice President, Strategic Partnering and Transactions at Malvern Consulting Group from February 2012 through October 2012. He was appointed as Secretary in September 2013. Prior to joining us, Mr. Sherman served as General Counsel at Actinium Pharmaceuticals, Inc. from June 2004 through September 2012 and General Counsel at Hawaii Biotech, Inc., or Hawaii Biotech, from January 2002 through July 2010. From 1992 through 2001, he was the founder and managing officer of QED Technologies, L.P., a life science business consulting firm purchased in 1999 by The Omnicom Group. Mr. Sherman was a partner in the law firm of Pepper, Hamilton & Scheetz (now Pepper Hamilton LLP) from 1990 through 1992. He also spent more than a decade as Deputy General Counsel of SmithKline Beckman Corporation (now GlaxoSmithKline), from 1976 through 1989.
Mr. Sherman is also a principal in a private Small Business Investment Company investment fund, CIP Capital L.P., and a venture partner in the SCP/Vitalife family of funds in suburban Philadelphia. Mr. Sherman currently serves as a member of the board of directors of Hawaii Biotech (2005 to present) and Immunomedics, Inc. (NASDAQ: IMMU) (August 2013 to present) and formerly served as a member of the board of directors of Functional Technologies, Inc. (May 2011 to June 2013) and Leversense LLC (March 2011 to February 2013). He graduated magna cum laude with a B.A. in political science and economics from the University of Nebraska in 1968, where he was elected to Phi Beta Kappa. As a Root-Tilden Scholar at the New York University School of Law, he received his Juris Doctor degree in 1971.
...
Stockholders intending to present proposals at our Annual Meeting of Stockholders to be held in 2015 and intending to have such proposals included in our next proxy statement must send their proposals to our Secretary, Richard L. Sherman, in writing, at TetraLogic Pharmaceuticals Corporation, 343 Phoenixville Pike, Malvern, PA 19355 pursuant to Rule 14a-8 promulgated under the Exchange Act for inclusion in our proxy statement and form of proxy for our 2015 Annual Meeting of Stockholders and must be received by us not later than December 5, 2014.
...
We will promptly deliver a separate copy of any such documents to you if you write or call our Secretary, Richard L. Sherman, at TetraLogic Pharmaceuticals Corporation, 343 Phoenixville Pike, Malvern, PA 19355 or 610-889-9900.
If you want to receive separate copies of our Proxy Statement and Annual Report in the future, or if you are receiving multiple copies and would like to receive only one copy for your household, you should contact your bank, broker, or other nominee record holder, or you may contact our Secretary, in writing, at the address listed above.
By Order of the Board of Directors,
/s/ RICHARD L. SHERMAN
...
Richard L. Sherman, Secretary

Similar Profiles

Other People with this Name

Other people with the name Sherman

David Sherman
Visy Pty Ltd

Norman Sherman
The Policy Centre for Victim Issues

Ken Sherman
Coral Medical Health Spa

Vicki Sherman
Naylor , LLC

Amy Sherman
The Miami Herald

City Directory Icon

Browse ZoomInfo's Business Contact Directory by City

People Directory Icon

Browse ZoomInfo's
Business People Directory

Company Directory Icon

Browse ZoomInfo's
Advanced Company Directory